“In my view, all that is necessary for faith is the belief that by doing our best we shall succeed in our aims: the improvement of mankind.”
Wendy Holman and her team are driven by a focused determination to help alleviate human suffering. Through the development and investment in therapies and diagnostic tools which focus on under-represented patient populations, they are working to achieve their goals. Wendy Holman is the CEO and co-founder of Ridgeback Biotherapeutics a biotechnology company focused on pediatric and orphan infectious diseases. Prior to joining Ridgeback, Ms. Holman worked at US-based ZBI Equities, a multi-billion dollar public equity investment fund and its parent company, Ziff Brothers Investments. Between 1999 and 2014 she held various positions including healthcare sector head and director of research at ZBI Equities, and Principal at Ziff Brothers Investments. Wendy graduated from the University of Pennsylvania’s Wharton school and serves on the Board of Overseers for the Penn Libraries. She is the campaign chair for the University of Pennsylvania’s new Biotech Commons.